Bioinformatics

Genalyte Receives National Cancer Institute Grant

By Brad Webb / October 21, 2013 / 0 Comments

Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a  diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability […]

Read More

Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer

By Ted Driscoll / September 28, 2013 / 0 Comments

Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer. NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a […]

Read More

Genalyte and Colorado Diabetes Center Collaborate on Type 1 Diabetes

By Brad Webb / August 18, 2013 / 0 Comments

Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents […]

Read More

NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.

By Brad Webb / June 20, 2013 / 0 Comments

Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC.  The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of […]

Read More

Congratulations to Natera on Completing $54.6 Million Financing to Support Expansion

By Ted Driscoll / May 3, 2013 / 0 Comments

Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February […]

Read More

Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data

By Claremont Creek Alerts / February 23, 2013 / 0 Comments

February 20, 2013   source: the original post by Ed Silverman appeared in Pharmalot As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives